4/12
08:00 am
arqt
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $16.00 price target on the stock.
High
Report
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $16.00 price target on the stock.
4/12
06:43 am
arqt
Rating for ARQT
High
Report
Rating for ARQT
4/12
06:43 am
arqt
Rating for ARQT
High
Report
Rating for ARQT
2/28
11:20 am
arqt
Rating for ARQT
Low
Report
Rating for ARQT
2/28
11:20 am
arqt
Rating for ARQT
Low
Report
Rating for ARQT
2/28
11:20 am
arqt
Rating for ARQT
Low
Report
Rating for ARQT
2/28
08:52 am
arqt
Rating for ARQT
Low
Report
Rating for ARQT
2/28
08:52 am
arqt
Rating for ARQT
Low
Report
Rating for ARQT
2/28
07:37 am
arqt
Rating for ARQT
Low
Report
Rating for ARQT
2/28
07:37 am
arqt
Rating for ARQT
Low
Report
Rating for ARQT
2/23
10:56 am
arqt
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at Mizuho. They now have a $16.00 price target on the stock, up previously from $8.00.
Low
Report
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at Mizuho. They now have a $16.00 price target on the stock, up previously from $8.00.
2/23
10:56 am
arqt
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at Mizuho. They now have a $16.00 price target on the stock, up previously from $8.00.
Low
Report
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at Mizuho. They now have a $16.00 price target on the stock, up previously from $8.00.
2/23
10:25 am
arqt
Rating for ARQT
Low
Report
Rating for ARQT
2/23
10:25 am
arqt
Rating for ARQT
Low
Report
Rating for ARQT